Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 4
Submit an article Journal homepage
542
Views
13
CrossRef citations to date
0
Altmetric
Letters to the Editor

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Pier Luigi ZinzaniInstitute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy; View further author information
,
Robert ChenHematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; View further author information
,
Philippe ArmandMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Nathalie A. JohnsonDepartment of Hematology, Jewish General Hospital, Montreal, QC, Canada; View further author information
,
Pauline BriceHematology-Oncology, Hôpital Saint-Louis, Paris, France; View further author information
,
John RadfordDivision of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; ORCID Iconhttp://orcid.org/0000-0001-7898-2786View further author information
ORCID Icon,
Vincent RibragDITEP, Insitut Gustave Roussy, Villejuif, France; View further author information
,
Daniel MolinImmunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden; View further author information
,
Theodoros P. VassilakopoulosHematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; View further author information
,
Akihiro TomitaHematology and Oncology, Fujita Health University School of Medicine, Toyoake, Japan; View further author information
,
Bastian von TresckowDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany; View further author information
,
Margaret A. ShippHematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Jianxin LinMedical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA; View further author information
,
Akash NaharMedical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA; View further author information
,
Arun BalakumaranMedical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA; View further author information
&
Craig H. MoskowitzDepartment of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USACorrespondence[email protected]
View further author information
 show all
Pages 950-954 | Received 01 Aug 2019, Accepted 27 Nov 2019, Published online: 06 Jan 2020

References

  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma (Version 2.2019). [cited 2019 Jul 23]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.
  • Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin disease. Br J Haematol. 2004;124(5):645–652.
  • Akhtar S, El Weshi A, Abdelsalam M, et al. Primary refractory Hodgkin lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant. 2007;40(7):651–658.
  • Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
  • Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016;17(9):1283–1294.
  • Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma. N Engl J Med. 2015;372(4):311–319.
  • Chen R, Zinzani PL, Lee HJ, et al. Pembrolizuamb in relapsed or refractory Hodgkin lymphoma. Two-year follow up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320–324.
  • Moskowitz AJ, Hamlin PA Jr., Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460.
  • Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.